咽頭炎治療の世界市場レポート 2025年

咽頭炎治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.0％で29億9,000万米ドルに成長します。予測期間の成長は、迅速なポイントオブケア検査の採用、個別化医療の需要、抗生物質耐性の蔓延、手指衛生の重要性の高まりに起因します。予測期間の主な動向には、咽頭炎治療薬の研究開発の進展、デジタルヘルス技術、遠隔医療統合、などがあります。

連鎖球菌性咽頭炎のトランスミッションの増加は、咽頭炎治療市場の拡大を牽引する構えです。溶連菌感染症は、主に咽頭と扁桃腺を侵す伝染性の細菌感染症です。抗生物質による溶連菌感染症の迅速かつ効果的な治療は、症状の緩和、合併症の予防、他者への感染リスクの低減のために極めて重要です。例えば、2022年6月現在、米国の政府機関である疾病対策予防センターのデータによると、米国では侵襲性A群溶連菌感染症が年間約14,000～25,000件発生しています。さらに、溶連菌関連疾患は毎年520万人の外来受診を促し、280万件の抗生物質処方をもたらしています。このように、溶連菌感染症のトランスミッションの増加は、咽頭炎治療市場の成長を大きく促進する要因となっています。

インフルエンザ罹患率の増加は、咽頭炎治療市場の成長を促進すると予想されます。一般的にインフルエンザと呼ばれるインフルエンザは、インフルエンザウイルスによって引き起こされる伝染性の呼吸器疾患です。咽頭炎治療は、喉の炎症や炎症など、インフルエンザの症状を管理するために一般的に使用されています。これらの治療は、不快感の緩和、アレルギーの緩和、肺炎や気管支炎などの合併症の予防を目的としています。例えば、2023年7月、スウェーデンに本拠を置く政府機関である欧州疾病予防管理センター（ECDC）は、EU/EEAにおける2022/2023年のインフルエンザシーズンにおいて、インフルエンザ検体の陽性率は2022年第51週に42％に達し、2023年第5週から第12週まで陽性率は28％前後で推移したと報告しました。その結果、インフルエンザ罹患率の上昇が咽頭炎治療市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界咽頭炎治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の咽頭炎治療市場：成長率分析
• 世界の咽頭炎治療市場の実績：規模と成長, 2019-2024
• 世界の咽頭炎治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界咽頭炎治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の咽頭炎治療市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ベータラクタム
• マクロライド
• セファロスポリン
• フルオロキノロン
• テトラサイクリン
• その他の薬物クラス
• 世界の咽頭炎治療市場感染源別、実績と予測, 2019-2024, 2024-2029F, 2034F
• バイラル
• 細菌性
• 世界の咽頭炎治療市場配送方法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 静脈内
• 筋肉内
• その他の配送方法
• 世界の咽頭炎治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門センター
• その他のエンドユーザー
• 世界の咽頭炎治療市場、ベータラクタムのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ペニシリン
• アモキシシリン
• アンピシリン
• 世界の咽頭炎治療市場マクロライドのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ペニシリン
• アモキシシリン
• アンピシリン
• 世界の咽頭炎治療市場セファロスポリンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• セフロキシム
• セフトリアキソン
• セフジニル
• 世界の咽頭炎治療市場、フルオロキノロンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• シプロフロキサシン
• レボフロキサシン
• モキシフロキサシン
• 世界の咽頭炎治療市場、テトラサイクリンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ドキシサイクリン
• ミノサイクリン
• テトラサイクリン
• 世界の咽頭炎治療市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• クリンダマイシン
• スルホンアミド
• カルバペネム

第7章 地域別・国別分析

• 世界の咽頭炎治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の咽頭炎治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 咽頭炎治療市場：競合情勢
• 咽頭炎治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis
  • Genentech Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Pliva Hrvatska D.o.o. Overview, Products and Services, Strategy and Financial Analysis
  • Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Medtronic plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Fresenius Kabi AG
• Bausch Health Companies Inc.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Cipla Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 咽頭炎治療市場2029：新たな機会を提供する国
• 咽頭炎治療市場2029：新たな機会を提供するセグメント
• 咽頭炎治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Pharyngitis treatment involves the care and management of individuals who are dealing with inflammation in the oropharynx, commonly referred to as the throat. Pharyngitis can have multiple causes, including bacterial or viral infections, allergies, trauma, malignancy, reflux, and exposure to certain toxins.

The primary classes of drugs used in pharyngitis treatment encompass beta-lactams, macrolides, cephalosporins, fluoroquinolones, tetracyclines, and other categories. Beta-lactams are a class of antibiotics distinguished by the presence of a beta-lactam ring in their chemical structure. Infections can stem from various sources, including viral and bacterial agents. Additionally, treatments are administered through various modes, such as oral, intravenous, intramuscular, and others, catering to diverse end-users, including hospitals, homecare settings, specialty centers, and more.

The pharyngitis treatment market research report is one of a series of new reports from The Business Research Company that provides pharyngitis treatment market statistics, including pharyngitis treatment industry global market size, regional shares, competitors with a pharyngitis treatment market share, detailed pharyngitis treatment market segments, market trends and opportunities and any further data you may need to thrive in the pharyngitis treatment industry. This pharyngitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pharyngitis treatment market size has grown steadily in recent years. It will grow from $2.27 billion in 2024 to $2.37 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to high prevalence and growing incidence of flu, rising prevalence of pharyngitis, growing awareness of pharyngitis, increasing access to healthcare, rising disposable incomes.

The pharyngitis treatment market size is expected to see strong growth in the next few years. It will grow to $2.99 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to adoption of rapid point-of-care tests, demand for personalized medicine, prevalence of antibiotic resistance, rising importance of hand hygiene. Major trends in the forecast period include advancements in research and development of pharyngitis therapies, digital health technologies, telehealth integration,.

The increasing transmission of strep throat is poised to drive the expansion of the pharyngitis treatment market. Strep throat is a contagious bacterial infection primarily affecting the throat and tonsils. Swift and effective treatment of strep throat with antibiotics is crucial for symptom relief, complication prevention, and reducing the risk of spreading the infection to others. For example, as of June 2022, data from the Centers for Disease Control and Prevention, a US-based government agency, reveals an annual occurrence of approximately 14,000 to 25,000 cases of invasive group A strep disease in the United States. Furthermore, strep-related diseases prompt 5.2 million outpatient visits and result in 2.8 million antibiotic prescriptions each year. Thus, the increased transmission of strep throat is a significant driver of growth in the pharyngitis treatment market.

The increasing incidence of influenza is expected to drive the growth of the pharyngitis treatment market. Influenza, commonly referred to as the flu, is a contagious respiratory illness caused by influenza viruses. Pharyngitis treatment is commonly used to manage the symptoms of influenza, including inflammation and irritation of the throat. These treatments are aimed at alleviating discomfort, relieving allergies, and preventing complications such as pneumonia and bronchitis. For example, in July 2023, the European Centre for Disease Prevention and Control (ECDC), a Sweden-based government agency, reported that during the 2022/2023 influenza season in the EU/EEA, the percentage of positive influenza specimens reached 42% in week 51 of 2022, with positivity remaining around 28% from week 5 to week 12 of 2023. As a result, the rising incidence of influenza is driving the growth of the pharyngitis treatment market.

Major companies operating in the pharyngitis treatment market are focusing on developing innovative solutions like oral monotherapy to improve patient compliance and offer effective, convenient treatment options. Oral monotherapy refers to using a single medication administered orally to treat a specific condition, rather than combining multiple treatments. This approach simplifies the treatment regimen while delivering the desired therapeutic effect. For example, in December 2023, Novartis AG, a Switzerland-based pharmaceutical company, received FDA approval for Fabhalta (iptacopan), marking it as the first oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria (PNH). This approval provides a significant advancement by offering a new treatment that enhances hemoglobin levels, removing the need for blood transfusions.

In November 2022, TPG Inc., a US-based private equity firm, acquired a majority stake in iNova Pharmaceuticals for $1.3 billion (USD 2 billion). This acquisition aims to accelerate growth, expand market reach, and enhance product offerings in the healthcare sector, particularly in Southeast and North Asia. iNova Pharmaceuticals, based in Singapore, provides over-the-counter products designed to relieve symptoms of pharyngitis, including throat lozenges and pain relievers.

Major companies operating in the pharyngitis treatment market are Pfizer Inc., GlaxoSmithKline PLC, Genentech Inc., Pliva Hrvatska D.o.o., Viatris Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Pliva Hrvatska D.o.o., LivaNova PLC, Genentech Inc.

North America was the largest region in the pharyngitis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pharyngitis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pharyngitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pharyngitis treatment market consists of sales of antibiotics, antiviral drugs and antifungal medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pharyngitis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pharyngitis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pharyngitis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pharyngitis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Beta Lactams; Macrolides; Cephalosporins; Fluoroquinolones; Tetracycline; Other Drug Classes
• 2) By Source of Infection: Viral; Bacterial
• 3) By Modes Of Delivery: Oral; Intravenous; Intramuscular; Other Modes Of Delivery
• 4) By End-Users: Hospitals; Homecare; Specialty Centers; Other End-Users
• Subsegments:
• 1) By Beta Lactams: Penicillins; Amoxicillin; Ampicillin
• 2) By Macrolides: Erythromycin; Azithromycin; Clarithromycin
• 3) By Cephalosporins: Cefuroxime; Ceftriaxone; Cefdinir
• 4) By Fluoroquinolones: Ciprofloxacin; Levofloxacin; Moxifloxacin
• 5) By Tetracycline: Doxycycline; Minocycline; Tetracycline
• 6) By Other Drug Classes: Clindamycin; Sulfonamides; Carbapenems
• Companies Mentioned: Pfizer Inc.; GlaxoSmithKline PLC; Genentech Inc.; Pliva Hrvatska D.o.o.; Viatris Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pharyngitis Treatment Market Characteristics

3. Pharyngitis Treatment Market Trends And Strategies

4. Pharyngitis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Pharyngitis Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Pharyngitis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Pharyngitis Treatment Market Growth Rate Analysis
• 5.4. Global Pharyngitis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Pharyngitis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Pharyngitis Treatment Total Addressable Market (TAM)

6. Pharyngitis Treatment Market Segmentation

• 6.1. Global Pharyngitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Beta Lactams
• Macrolides
• Cephalosporins
• Fluoroquinolones
• Tetracycline
• Other Drug Classes
• 6.2. Global Pharyngitis Treatment Market, Segmentation By Source of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Viral
• Bacterial
• 6.3. Global Pharyngitis Treatment Market, Segmentation By Modes Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Intramuscular
• Other Modes Of Delivery
• 6.4. Global Pharyngitis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Centers
• Other End-Users
• 6.5. Global Pharyngitis Treatment Market, Sub-Segmentation Of Beta Lactams, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Penicillins
• Amoxicillin
• Ampicillin
• 6.6. Global Pharyngitis Treatment Market, Sub-Segmentation Of Macrolides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Penicillins
• Amoxicillin
• Ampicillin
• 6.7. Global Pharyngitis Treatment Market, Sub-Segmentation Of Cephalosporins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cefuroxime
• Ceftriaxone
• Cefdinir
• 6.8. Global Pharyngitis Treatment Market, Sub-Segmentation Of Fluoroquinolones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ciprofloxacin
• Levofloxacin
• Moxifloxacin
• 6.9. Global Pharyngitis Treatment Market, Sub-Segmentation Of Tetracycline, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Doxycycline
• Minocycline
• Tetracycline
• 6.10. Global Pharyngitis Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clindamycin
• Sulfonamides
• Carbapenems

7. Pharyngitis Treatment Market Regional And Country Analysis

• 7.1. Global Pharyngitis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Pharyngitis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pharyngitis Treatment Market

• 8.1. Asia-Pacific Pharyngitis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Pharyngitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Pharyngitis Treatment Market, Segmentation By Source of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Pharyngitis Treatment Market, Segmentation By Modes Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pharyngitis Treatment Market

• 9.1. China Pharyngitis Treatment Market Overview
• 9.2. China Pharyngitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Pharyngitis Treatment Market, Segmentation By Source of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Pharyngitis Treatment Market, Segmentation By Modes Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pharyngitis Treatment Market

• 10.1. India Pharyngitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Pharyngitis Treatment Market, Segmentation By Source of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Pharyngitis Treatment Market, Segmentation By Modes Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pharyngitis Treatment Market

• 11.1. Japan Pharyngitis Treatment Market Overview
• 11.2. Japan Pharyngitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Pharyngitis Treatment Market, Segmentation By Source of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Pharyngitis Treatment Market, Segmentation By Modes Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pharyngitis Treatment Market

• 12.1. Australia Pharyngitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Pharyngitis Treatment Market, Segmentation By Source of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Pharyngitis Treatment Market, Segmentation By Modes Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pharyngitis Treatment Market

• 13.1. Indonesia Pharyngitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Pharyngitis Treatment Market, Segmentation By Source of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Pharyngitis Treatment Market, Segmentation By Modes Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pharyngitis Treatment Market

• 14.1. South Korea Pharyngitis Treatment Market Overview
• 14.2. South Korea Pharyngitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Pharyngitis Treatment Market, Segmentation By Source of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Pharyngitis Treatment Market, Segmentation By Modes Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pharyngitis Treatment Market

• 15.1. Western Europe Pharyngitis Treatment Market Overview
• 15.2. Western Europe Pharyngitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Pharyngitis Treatment Market, Segmentation By Source of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Pharyngitis Treatment Market, Segmentation By Modes Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pharyngitis Treatment Market

• 16.1. UK Pharyngitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Pharyngitis Treatment Market, Segmentation By Source of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Pharyngitis Treatment Market, Segmentation By Modes Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pharyngitis Treatment Market

• 17.1. Germany Pharyngitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Pharyngitis Treatment Market, Segmentation By Source of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Pharyngitis Treatment Market, Segmentation By Modes Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pharyngitis Treatment Market

• 18.1. France Pharyngitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Pharyngitis Treatment Market, Segmentation By Source of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Pharyngitis Treatment Market, Segmentation By Modes Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pharyngitis Treatment Market

• 19.1. Italy Pharyngitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Pharyngitis Treatment Market, Segmentation By Source of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Pharyngitis Treatment Market, Segmentation By Modes Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pharyngitis Treatment Market

• 20.1. Spain Pharyngitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Pharyngitis Treatment Market, Segmentation By Source of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Pharyngitis Treatment Market, Segmentation By Modes Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pharyngitis Treatment Market

• 21.1. Eastern Europe Pharyngitis Treatment Market Overview
• 21.2. Eastern Europe Pharyngitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Pharyngitis Treatment Market, Segmentation By Source of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Pharyngitis Treatment Market, Segmentation By Modes Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pharyngitis Treatment Market

• 22.1. Russia Pharyngitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Pharyngitis Treatment Market, Segmentation By Source of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Pharyngitis Treatment Market, Segmentation By Modes Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pharyngitis Treatment Market

• 23.1. North America Pharyngitis Treatment Market Overview
• 23.2. North America Pharyngitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Pharyngitis Treatment Market, Segmentation By Source of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Pharyngitis Treatment Market, Segmentation By Modes Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pharyngitis Treatment Market

• 24.1. USA Pharyngitis Treatment Market Overview
• 24.2. USA Pharyngitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Pharyngitis Treatment Market, Segmentation By Source of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Pharyngitis Treatment Market, Segmentation By Modes Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pharyngitis Treatment Market

• 25.1. Canada Pharyngitis Treatment Market Overview
• 25.2. Canada Pharyngitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Pharyngitis Treatment Market, Segmentation By Source of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Pharyngitis Treatment Market, Segmentation By Modes Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pharyngitis Treatment Market

• 26.1. South America Pharyngitis Treatment Market Overview
• 26.2. South America Pharyngitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Pharyngitis Treatment Market, Segmentation By Source of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Pharyngitis Treatment Market, Segmentation By Modes Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pharyngitis Treatment Market

• 27.1. Brazil Pharyngitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Pharyngitis Treatment Market, Segmentation By Source of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Pharyngitis Treatment Market, Segmentation By Modes Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pharyngitis Treatment Market

• 28.1. Middle East Pharyngitis Treatment Market Overview
• 28.2. Middle East Pharyngitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Pharyngitis Treatment Market, Segmentation By Source of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Pharyngitis Treatment Market, Segmentation By Modes Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pharyngitis Treatment Market

• 29.1. Africa Pharyngitis Treatment Market Overview
• 29.2. Africa Pharyngitis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Pharyngitis Treatment Market, Segmentation By Source of Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Pharyngitis Treatment Market, Segmentation By Modes Of Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pharyngitis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Pharyngitis Treatment Market Competitive Landscape
• 30.2. Pharyngitis Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Genentech Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Pliva Hrvatska D.o.o. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Pharyngitis Treatment Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceutical Industries Ltd.
• 31.2. AbbVie Inc.
• 31.3. Medtronic plc
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. Eli Lilly and Company
• 31.6. Gilead Sciences Inc.
• 31.7. Amgen Inc.
• 31.8. Boehringer Ingelheim International GmbH
• 31.9. Viatris Inc.
• 31.10. Teva Pharmaceutical Industries Ltd.
• 31.11. Fresenius Kabi AG
• 31.12. Bausch Health Companies Inc.
• 31.13. Sun Pharmaceutical Industries Ltd.
• 31.14. Dr. Reddy's Laboratories Ltd.
• 31.15. Cipla Limited

32. Global Pharyngitis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pharyngitis Treatment Market

34. Recent Developments In The Pharyngitis Treatment Market

35. Pharyngitis Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Pharyngitis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Pharyngitis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Pharyngitis Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer